Published in Clin Exp Immunol on March 01, 2012
Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1. Clin Exp Immunol (2012) 1.30
Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives. J Inflamm Res (2015) 1.16
Cytosolic double-stranded RNA activates the NLRP3 inflammasome via MAVS-induced membrane permeabilization and K+ efflux. J Immunol (2014) 0.94
RNase L activates the NLRP3 inflammasome during viral infections. Cell Host Microbe (2015) 0.90
Immunology in clinic review series; focus on autoinflammatory diseases: inflammasomes: mechanisms of activation. Clin Exp Immunol (2012) 0.90
A novel mutation in the interleukin-1 receptor antagonist associated with intrauterine disease onset. Clin Immunol (2012) 0.85
NOD-Like Receptors in Infection, Immunity, and Diseases. Yonsei Med J (2016) 0.83
Thorough investigation of a canine autoinflammatory disease (AID) confirms one main risk locus and suggests a modifier locus for amyloidosis. PLoS One (2013) 0.83
CAPS--pathogenesis, presentation and treatment of an autoinflammatory disease. Semin Immunopathol (2015) 0.82
Inflammasome in intestinal inflammation and cancer. Mediators Inflamm (2013) 0.82
Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean Fever. Inflammation (2015) 0.81
NLRP7 inter-domain interactions: the NACHT-associated domain is the physical mediator for oligomeric assembly. Mol Hum Reprod (2014) 0.78
Neutrophil-lymphocyte ratio in children with familial Mediterranean fever: Original article. Eur J Rheumatol (2015) 0.78
CX3CR1(+) B cells show immune suppressor properties. J Biol Chem (2014) 0.77
Autoinflammatory syndromes. Dermatol Clin (2013) 0.77
Broadening the translational immunology landscape. Clin Exp Immunol (2012) 0.75
Increased prevalence of MEFV exon 10 variants in Japanese patients with adult-onset Still's disease. Clin Exp Immunol (2015) 0.75
Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature (2006) 24.43
The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell (2002) 20.11
Cryopyrin activates the inflammasome in response to toxins and ATP. Nature (2006) 18.74
Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol (2008) 16.65
Biologic basis for interleukin-1 in disease. Blood (1996) 16.04
NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity (2004) 13.55
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature (2010) 10.60
Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages. Nat Immunol (2006) 10.55
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature (2006) 9.77
Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf. Nat Immunol (2006) 9.64
Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet (2001) 9.34
Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol (2009) 9.24
Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol (2009) 8.40
The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol (2009) 7.80
The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol (2010) 7.47
Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol (2010) 6.64
Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature (2011) 6.38
Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol (2009) 5.91
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood (2011) 5.61
Innate immune detection of the type III secretion apparatus through the NLRC4 inflammasome. Proc Natl Acad Sci U S A (2010) 5.59
The P2X7 receptor: a key player in IL-1 processing and release. J Immunol (2006) 5.35
Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med (2009) 5.19
Regulation of Legionella phagosome maturation and infection through flagellin and host Ipaf. J Biol Chem (2006) 5.11
An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med (2009) 4.97
Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet (2002) 4.84
Differential regulation of caspase-1 activation, pyroptosis, and autophagy via Ipaf and ASC in Shigella-infected macrophages. PLoS Pathog (2007) 4.73
Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood (2008) 4.63
Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. Mol Cell (2007) 4.33
Differential requirement of P2X7 receptor and intracellular K+ for caspase-1 activation induced by intracellular and extracellular bacteria. J Biol Chem (2007) 4.27
Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity (2001) 4.23
Critical role for Ipaf in Pseudomonas aeruginosa-induced caspase-1 activation. Eur J Immunol (2007) 4.19
Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ (2006) 4.16
Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med (2000) 4.06
Intracellular DNA recognition. Nat Rev Immunol (2010) 3.70
Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum (2008) 3.36
Cutting edge: TNF-alpha mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. J Immunol (2009) 3.32
Caspase-1 independent IL-1beta production is critical for host resistance to mycobacterium tuberculosis and does not require TLR signaling in vivo. J Immunol (2010) 3.25
The secretory route of the leaderless protein interleukin 1beta involves exocytosis of endolysosome-related vesicles. Mol Biol Cell (1999) 3.24
Function of Nod-like receptors in microbial recognition and host defense. Immunol Rev (2009) 3.20
A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J Immunol (2011) 3.14
Listeria monocytogenes triggers AIM2-mediated pyroptosis upon infrequent bacteriolysis in the macrophage cytosol. Cell Host Microbe (2010) 3.09
Cutting edge: reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. J Immunol (2011) 3.05
Autoinflammatory disease reloaded: a clinical perspective. Cell (2010) 3.04
ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1beta and IL-18 secretion in an autocrine way. Proc Natl Acad Sci U S A (2008) 3.00
Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity (2009) 2.93
Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. Mol Cell (2007) 2.92
Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med (1991) 2.76
Inflammasome activation and IL-1β and IL-18 processing during infection. Trends Immunol (2011) 2.75
Superoxide dismutase 1 regulates caspase-1 and endotoxic shock. Nat Immunol (2008) 2.72
Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice. Immunity (2011) 2.69
The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A (2006) 2.59
A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity (2009) 2.59
Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell (2003) 2.55
Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med (2000) 2.50
The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ (2007) 2.49
Potentiation of caspase-1 activation by the P2X7 receptor is dependent on TLR signals and requires NF-kappaB-driven protein synthesis. J Immunol (2005) 2.49
Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling. Proc Natl Acad Sci U S A (2007) 2.48
Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease. Proc Natl Acad Sci U S A (2010) 2.38
Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med (1974) 2.35
Listeria monocytogenes is sensed by the NLRP3 and AIM2 inflammasome. Eur J Immunol (2010) 2.30
A critical role for hemolysins and bacterial lipoproteins in Staphylococcus aureus-induced activation of the Nlrp3 inflammasome. J Immunol (2009) 2.29
Cryopyrin-induced interleukin 1beta secretion in monocytic cells: enhanced activity of disease-associated mutants and requirement for ASC. J Biol Chem (2004) 2.26
Intracellular NOD-like receptors in innate immunity, infection and disease. Cell Microbiol (2007) 2.25
Inflammasomes: current understanding and open questions. Cell Mol Life Sci (2010) 1.87
Caspase-1-dependent processing of pro-interleukin-1beta is cytosolic and precedes cell death. J Cell Sci (2007) 1.80
Pyrin critical to macrophage IL-1beta response to Francisella challenge. J Immunol (2009) 1.73
Nucleotide-binding oligomerization domain-like receptors: intracellular pattern recognition molecules for pathogen detection and host defense. J Immunol (2006) 1.73
Regulation of cryopyrin/Pypaf1 signaling by pyrin, the familial Mediterranean fever gene product. Biochem Biophys Res Commun (2003) 1.71
Inflammasomes as microbial sensors. Eur J Immunol (2010) 1.70
Activation of the Nlrp3 inflammasome by Streptococcus pyogenes requires streptolysin O and NF-kappa B activation but proceeds independently of TLR signaling and P2X7 receptor. J Immunol (2009) 1.60
STAT3 tyrosine phosphorylation is critical for interleukin 1 beta and interleukin-6 production in response to lipopolysaccharide and live bacteria. Mol Immunol (2009) 1.59
Pyrin levels in human monocytes and monocyte-derived macrophages regulate IL-1beta processing and release. J Immunol (2007) 1.54
Involvement of absent in melanoma 2 in inflammasome activation in macrophages infected with Listeria monocytogenes. J Immunol (2010) 1.52
Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1. Clin Exp Immunol (2012) 1.30
Clathrin- and dynamin-dependent endocytic pathway regulates muramyl dipeptide internalization and NOD2 activation. J Immunol (2009) 1.26
P2X7 receptor-stimulated secretion of MHC class II-containing exosomes requires the ASC/NLRP3 inflammasome but is independent of caspase-1. J Immunol (2009) 1.25
Sterile inflammatory responses mediated by the NLRP3 inflammasome. Eur J Immunol (2010) 1.14
P-selectin glycoprotein ligand-1 regulates adhesive properties of the endothelium and leukocyte trafficking into adipose tissue. Circ Res (2010) 1.14
Interleukin-18 stimulates fibronectin expression in primary human cardiac fibroblasts via PI3K-Akt-dependent NF-kappaB activation. J Cell Physiol (2008) 1.03
Mechanism of impaired NLRP3 inflammasome priming by monophosphoryl lipid A. Sci Signal (2011) 1.03
Sensing cytoplasmic danger signals by the inflammasome. J Clin Immunol (2010) 1.02
Recurrent febrile syndromes: what a rheumatologist needs to know. Nat Rev Rheumatol (2009) 1.00
Calcium-independent phospholipase A2 beta is dispensable in inflammasome activation and its inhibition by bromoenol lactone. J Innate Immun (2009) 0.97
Fungal pathogen recognition by the NLRP3 inflammasome. Virulence (2010) 0.96
Immunology in clinic review series; focus on autoinflammatory diseases: inflammasomes: mechanisms of activation. Clin Exp Immunol (2012) 0.90
Inflammasomes and anti-viral immunity. J Clin Immunol (2010) 0.85
Pneumonia in a patient with familial Mediterranean fever successfully treated with anakinra--case report and review. Rheumatol Int (2010) 0.81
Role of a white collar-1-white collar-2 complex in blue-light signal transduction. EMBO J (1999) 2.20
Skeletal effects of early treatment of Class III malocclusion with maxillary expansion and face-mask therapy. Am J Orthod Dentofacial Orthop (1998) 1.72
Three-dimensional densitometric analysis of maxillary sutural changes induced by rapid maxillary expansion. Dentomaxillofac Radiol (2012) 1.66
Circadian regulation of the light input pathway in Neurospora crassa. EMBO J (2001) 1.65
Treatment timing for rapid maxillary expansion. Angle Orthod (2001) 1.47
Treatment timing for Twin-block therapy. Am J Orthod Dentofacial Orthop (2000) 1.37
Identification of protein antigens associated with the nuclear matrix and with clusters of interchromatin granules in both interphase and mitotic cells. J Cell Sci (1987) 1.29
Abnormalities of the maxillary incisors in children with cleft lip and palate. ASDC J Dent Child (1996) 1.23
Treatment and posttreatment craniofacial changes after rapid maxillary expansion and facemask therapy. Am J Orthod Dentofacial Orthop (2000) 1.16
Role of posterior transverse interarch discrepancy in Class II, Division 1 malocclusion during the mixed dentition phase. Am J Orthod Dentofacial Orthop (1996) 1.13
Changes in the blood coagulation, fibrinolysis, and cytokine profile during laparoscopic and open cholecystectomy. Surg Endosc (2004) 1.08
Rapid immunoperoxidase assay for detection of respiratory syncytial virus in nasopharyngeal secretions. J Clin Microbiol (1983) 1.07
Early dentofacial features of Class II malocclusion: a longitudinal study from the deciduous through the mixed dentition. Am J Orthod Dentofacial Orthop (1997) 1.05
Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells. Cell Death Differ (2006) 0.99
Glenoid fossa position in different facial types: a cephalometric study. Br J Orthod (1997) 0.95
Morphometric analysis of treatment effects of bone-anchored maxillary protraction in growing Class III patients. Eur J Orthod (2010) 0.92
A fungus among us: the Neurospora crassa circadian system. Semin Cell Dev Biol (2001) 0.90
A comparison of serum interleukin-6 concentrations in patients treated by cholecystectomy via laparotomy or laparoscopy. Hepatogastroenterology (2004) 0.89
[The transmigration of the permanent lower canine]. Minerva Stomatol (1991) 0.89
Islands of acetylated histone H4 in polytene chromosomes and their relationship to chromatin packaging and transcriptional activity. J Cell Sci (1990) 0.88
Mandibular skeletal changes induced by early functional treatment of Class III malocclusion: a superimposition study. Am J Orthod Dentofacial Orthop (1995) 0.85
Short-term effects of a modified Alt-RAMEC protocol for early treatment of Class III malocclusion: a controlled study. Orthod Craniofac Res (2014) 0.85
Class III malocclusion in the deciduous dentition: a morphological and correlation study. Eur J Orthod (1994) 0.83
Maturation of the middle phalanx of the third finger and cervical vertebrae: a comparative and diagnostic agreement study. Orthod Craniofac Res (2014) 0.83
Floating norms for the assessment of craniofacial pattern in the deciduous dentition. Eur J Orthod (1996) 0.83
Treatment protocol for the impaction of deciduous maxillary anterior teeth due to compound odontoma. Eur J Paediatr Dent (2012) 0.82
Craniofacial changes induced by early functional treatment of Class III malocclusion. Am J Orthod Dentofacial Orthop (1996) 0.81
Reduced E-cadherin expression correlates with unfavorable prognosis in adenoid cystic carcinoma of salivary glands of the oral cavity. Am J Clin Pathol (1999) 0.80
Tooth agenesis: dento-skeletal characteristics in subjects with orthodontic treatment need. Eur J Paediatr Dent (2011) 0.80
[The dentomaxillofacial characteristics of the Prader-Labhart-Willi syndrome. A clinical case report]. Minerva Stomatol (1991) 0.79
Thin-plate spline analysis of treatment effects of rapid maxillary expansion and face mask therapy in early Class III malocclusions. Eur J Orthod (1999) 0.79
Lateral cephalometric standards of Germans with normal occlusion from 6 to 17 years of age. J Orofac Orthop (2013) 0.78
Reversal of bronchial obstruction in children with mild stable asthma by aerosolized furosemide. Pediatr Pulmonol (1994) 0.78
Immunohistochemical evaluation of prostatic carcinoma before and after radiotherapy. J Urol (1980) 0.77
[Parathyroidectomy: bilateral exploration of the neck vs minimally invasive radioguided treatment]. Minerva Chir (2005) 0.77
Eruption anomalies of the maxillary permanent cuspids in children with cleft lip and/or palate. J Clin Pediatr Dent (1996) 0.77
Radioreceptor assay of an endothelin A receptor antagonist in plasma and urine. Clin Chem (1998) 0.76
Surface corrosion and fracture resistance of two nickel-titanium-based archwires induced by fluoride, pH, and thermocycling. An in vitro comparative study. Eur J Orthod (2010) 0.76
Correlation between fetal movement revealed in actography and fetal-neonatal well-being: observational study on 3,805 pregnancies followed in a Northern Italy tertiary care hospital. Clin Exp Obstet Gynecol (2011) 0.76
Friction in a hybrid system. An in vitro study. Oral Implantol (Rome) (2011) 0.75
To beam or not to beam: that is the question. Dentomaxillofac Radiol (2013) 0.75
[Isolation regional perfusion]. Suppl Tumori (2002) 0.75
[Rubella epidemic of 1977: sero-epidemiological study of the maternal and neonatal population made in Turin at the Maria Vittoria Hospital in the period July 1977-April 1978]. Ann Sclavo (1981) 0.75
[In vitro, activity of a new macrolide (RU 28965) against Chlamydia trachomatis and Ureaplasma urealyticum]. G Ital Chemioter (1986) 0.75
[Emergency resuscitation of severely burned patients]. Omnia Med Ther (1968) 0.75
Radiographic assessment of maxillary incisor position after rapid maxillary expansion in children with clinical signs of eruption disorder. J Orofac Orthop (2013) 0.75
Antiviral compounds. XVII - Synthesis and in vitro antiviral activity of 1-substituted 2-chloro- and 2-methoxyindole-3-carboxaldehyde thiosemicarbazones. Farmaco Sci (1981) 0.75
Correlation between histochemically assessed hormonal receptor content and clinical course in breast cancer. Presentation of 1,005 cases. Oncology (1991) 0.75
[Research on substances with antiviral activity. II. Derivatives of N-substituted 2-chloro-3-formylindoles]. Farmaco Sci (1975) 0.75
[Research on substances with antiviral activity. VIII. Benzindanoncarboxylic acids]. Farmaco Sci (1978) 0.75
Shape-coordinate and tensor analysis of skeletal changes in children with treated Class III malocclusions. Am J Orthod Dentofacial Orthop (1997) 0.75
Study of foetal hip: intrauterine positions and sonographic aspects. J Perinat Med (1994) 0.75
[The remote results of vasal sutures with the Nakayama forceps. II]. Atti Accad Fisiocrit Siena Med Fis (1966) 0.75
[Continuous digestive aspiration in surgery]. Atti Accad Fisiocrit Siena Med Fis (1966) 0.75
Associated dental anomalies in an Etruscan adolescent. Angle Orthod (1995) 0.75
[Polyuria in childhood]. Atti Accad Fisiocrit Siena Med Fis (1965) 0.75
[Slipped capital femoral epiphysis and biosynthetic growth hormone therapy. A case report]. Minerva Pediatr (1994) 0.75
[Postoperative arterial hypotension caused by neuroleptics and its treatment with dihydrogenated ergot alkaloids]. Atti Accad Fisiocrit Siena Med Fis (1966) 0.75
[Decrease of the curariform activity of succinylcholine by cholinesterase reactivator. (Results obtained in 60 patients treated with RP 7676]. Atti Accad Fisiocrit Siena Med Fis (1966) 0.75
Studies on potential antiviral compounds, XXII. Synthesis and in vitro antiviral activity of 1-(hydroxyalkyl)-1H-benzimidazoles. Arch Pharm (Weinheim) (1982) 0.75
[Emergency respiratory resuscitation in acute trichloroethylene poisoning]. Omnia Med Ther (1968) 0.75
[Closed injuries of the thorax]. Atti Accad Fisiocrit Siena Med Fis (1966) 0.75
[Substances with antiviral activity. XIII. Synthesis and in vitro activity of thiosemicarbazones of 1-benzoyl- and 1-benzyl-2-chloro-3-formylindoles]. Farmaco Sci (1980) 0.75
Studies on potential antiviral compounds, XI. Thiosemicarbazones of hydroaromatic ketones. Arch Pharm (Weinheim) (1981) 0.75
[The correlations between the echographic aspect of the perioral and masticatory muscles and dento-skeletal characteristics]. Radiol Med (1998) 0.75
[Correlation between receptor status histochemically determined and clinical course in tumors of the breast: execution and extension of the study]. Pathologica (1988) 0.75
[Substances having antiviral activity. IX. Synthesis and antiviral activity of 1-acyl-2-halo-3-formylindole thiosemicarbazones]. Farmaco Sci (1978) 0.75
C4. Maternal cardiac changes during uncomplicated twin pregnancy: does the chorionicity matter? J Matern Fetal Neonatal Med (2016) 0.75
[A current update on the etiopathogenesis of palatoschisis]. Minerva Stomatol (1992) 0.75
[Synergism of action of dipyridamole combined with bamethan administered by intravenous infusion in senile cerebral circulatory disturbances]. Clin Ter (1972) 0.75
[Research on substances with antiviral activity. VII. Activity and lipophilic of property N-alkyl-2-chloro-3-formylindole thiosemicarbazone]. Farmaco Sci (1977) 0.75